News Archive
A new study by researchers at the University of Iowa and published on the preprint server bioRxiv in August 2020 reports the utility of a mouse model that recapitulates several aspects of human COVID-19 and can reflect the antiviral efficacy of new drugs as well.
Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.
The connection between vitamin D levels and certain forms of cancer has been suspected for some time but now German researchers have come up with clear proof of the link.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Idealâ„¢ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Idealâ„¢ BioStent.
Over the years researchers have made tremendous strides in the understanding and treatment of cancer by searching genomes for links between genetic alterations and disease.
› Verified 2 days ago